Missouri AG warns Lilly to stop requiring data from hospitals seeking 340B drug discounts
The state disputes claims-data conditions for discounted hospital drug purchases; Lilly has previously defended its policy.
TL;DR
- Missouri’s attorney general told Eli Lilly to stop requiring hospital claims data as a condition of 340B pricing.
- The state alleges the conditions violate Missouri law, a claim that has not been established by a court in the cited material.
- Lilly previously said the data help detect fraud and duplicate discounts.
Missouri Attorney General Catherine Hanaway sent Eli Lilly a cease-and-desist letter dated 2026-10-26 over claims-data requirements tied to the federal 340B drug-discount program. STAT reported that the state asked Lilly to end the policy in Missouri. [1] [2]
Hanaway’s office said University of Missouri Health Care lost 340B pricing in July and later agreed to provide data while reserving its rights. The office alleged that the conditions violate Missouri law; those are allegations, not a court finding. [2] [3]
In a statement from 2026-01-29, Lilly said it had extended claims-data collection to all pharmacy purchases. The company argued that the data help identify fraud, abuse and unlawful duplicate discounts. [3] [4]
JBizNews reported that the state sought confirmation within 30 days that Lilly had stopped the policy in Missouri and stopped using the information. Its report did not include a new Lilly response to the Missouri letter. [3]
Why it matters
The dispute concerns how manufacturers’ data requirements interact with discounted drug purchasing by eligible hospitals, with possible implications for purchasing and compliance costs.
Editor's note
carried over from the 2026-10-28 pool; not previously published. Missouri’s claims are allegations, and Lilly’s cited defense predates the state letter; the accessible STAT article is partly paywalled.